CAMP4 announces an oversubscribed private placement of up to $100 million to advance a first-in-class treatment for SYNGAP1-Related Disorders.
The financing is led by Coastlands Capital with participation from new and existing investors.
The proceeds will fund the Phase 1/2 clinical trial in patients with SYNGAP1-related disorders.
Financing Details
Up to $100 million in gross proceeds through a private placement with an initial upfront financing of $50 million.
Leadership Changes
Dr. Doug Williams to become Board Chair and Dr. Dan Tardiff elevated to Chief Scientific Officer.
Investor Participation
Investors include Coastlands Capital, Janus Henderson Investors, Vivo Capital, and others.
- The financing will enable CAMP4 to advance its SYNGAP1 program into clinical development.
- The leadership changes signify a strategic move to enhance the company's scientific capabilities.
CAMP4 is well positioned to bring potential first-in-class treatments for genetic diseases into clinical trials with the support of this financing and leadership changes.